ARWR ▲ +0.4% - Arrowhead Pharmaceuticals, Inc. $ARWR - Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia Arrowhead Pharmaceuticals rose 0.4% on the announcement of interim topline clinical data for its dual-functional RNAi therapeutic candidate targeting mixed hyperlipidemia, a condition affecting cholesterol and triglyceride levels. The disclosure of clinical progress in a novel therapeutic approach supported modest buying interest in the stock. 15-SEP-2026 07:40 AM ET